References
- Iwasaki K, Kitsugi Y, Ikeda K, et al. (2016). In vivo individual variations in pharmacokinetics of efavirenz in cynomolgus monkeys genotyped for cytochrome P450 2C9. Biopharm Drug Dispos 37:379–83
- Poulin P, Haddad S. (2013). Hepatocyte composition-based model as a mechanistic tool for predicting the cell suspension: aqueous phase partition coefficient of drugs in in vitro metabolic studies. J Pharm Sci 102:2806–18
- Shida S, Utoh M, Murayama N, et al. (2015). Human plasma concentrations of cytochrome P450 probes extrapolated from pharmacokinetics in cynomolgus monkeys using physiologically based pharmacokinetic modeling. Xenobiotica 45:881–6
- Shiohira H, Yasui-Furukori N, Tateishi T, Uno T. (2011). Chiral assay of omeprazole and metabolites and its application to a pharmacokinetics related to CYP2C19 genotypes. J Chromatogr B Analyt Technol Biomed Life Sci 879:2465–70
- Uehara S, Inoue T, Utoh M, et al. (2016a). Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol, and midazolam, in common marmosets (Callithrix jacchus). Xenobiotica 46:163–8
- Uehara S, Kawano M, Murayama N, et al. (2016b). Oxidation of R- and S-omeprazole stereoselectively mediated by liver microsomal cytochrome P450 2C19 enzymes from cynomolgus monkeys and common marmosets. Biochem Pharmacol 120:56–62
- Uehara S, Uno Y, Inoue S, et al. (2015). Novel marmoset cytochrome P450 2C19 in livers efficiently metabolizes human P450 2C9 and 2C19 substrates, S-warfarin, tolbutamide, flurbiprofen, and omeprazole. Drug Metab Dispos 43:1408–16
- Uehara S, Uno Y, Inoue T, et al. (2016c). Individual differences in metabolic clearance of S-warfarin efficiently mediated by polymorphic marmoset cytochrome P450 2C19 in livers. Drug Metab Dispos 44:911–15
- Uno Y, Uehara S, Yamazaki H. (2016). Utility of non-human primates in drug development: comparison of non-human primate and human drug-metabolizing cytochrome P450 enzymes. Biochem Pharmacol 121:1–7
- Utoh M, Kusama T, Miura T, et al. (2017a). R-Warfarin clearances from plasma associated with polymorphic cytochrome P450 2C19 and simulated by individual physiologically based pharmacokinetic models for 11 cynomolgus monkeys. Xenobiotica. [Epub ahead of print]. http://dx.doi.org/10.1080/00498254.2017.1288945
- Utoh M, Miura T, Kusama T, et al. (2017b). Efavirenz clearances in vitro and in vivo in six cynomolgus monkeys associated with polymorphic cytochrome P450 2C9 and simulated by individual physiologically based pharmacokinetic models. Biopharm Drug Dispos 38:439–42
- Utoh M, Suemizu H, Mitsui M, et al. (2016). Human plasma concentrations of cytochrome P450 probe cocktails extrapolated from pharmacokinetics in mice transplanted with human hepatocytes and from pharmacokinetics in common marmosets using physiologically based pharmacokinetic modeling. Xenobiotica 46:1049–55
- Utoh M, Yoshikawa T, Hayashi Y, et al. (2015). Slow R-warfarin 7-hydroxylation mediated by P450 2C19 genetic variants in cynomolgus monkeys in vivo. Biochem Pharmacol 95:110–14
- Yamazaki H, Suemizu H, Mitsui M, et al. (2016). Combining chimeric mice with humanized liver, mass spectrometry, and physiologically-based pharmacokinetic modeling in toxicology. Chem Res Toxicol 29:1903–11